Major Depressive Disorder (MDD) is one of the leading causes of disability, morbidity, and mortality around the world with approximately 264 million people worldwide and an estimated 21 million adults in the US reporting symptoms of depression. The purpose of this study is to learn more about the benefits and safety of 80 mg daily of NMRA-335140 (Navacaprant) relative to a placebo will help in the treatment of major depressive disorder and how safe it is when administered to adults.
The potential benefits to participants would be study-related medical care at no-cost and knowledge gained about their condition. On a wider scale, there may be general benefits to society because the investigational treatment may become a future treatment option.
CONTACT US ABOUT DEPRESSION TRIAL